Last updated on May 2018

Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata


Brief description of study

This study will evaluate the safety and efficacy of CTP-543 in adult patients with chronic, moderate to severe alopecia areata.

Detailed Study Description

This is a double-blind, randomized, placebo-controlled multi-center study consisting of 2 cohorts to assess the safety and efficacy of CTP-543. Each Cohort will be initiated sequentially in ascending dose order. Subjects will be randomized to either an active dose of CTP-543 or placebo for a 24-week treatment period.

Clinical Study Identifier: NCT03137381

Contact Investigators or Research Sites near you

Start Over

Study Director

University of California, Irvine
Irvine, CA United States

Study Director

Contour Dermatology & Cosmetic Surgery Center
Rancho Mirage, CA United States

Study Director

Stanford University School of Medicine
Redwood City, CA United States

Study Director

Kaiser Permanente Northern California
San Francisco, CA United States

Study Director

Yale School of Medicine
New Haven, CT United States

Study Director

Northwestern University
Chicago, IL United States

Study Director

Minnesota Clinical Study Center
Fridley, MN United States

Study Director

Icahn School of Medicine at Mt. Sinai
New York, NY United States

Study Director

Columbia University
New York, NY United States

Study Director

Wake Forest University Health Sciences
Winston-Salem, NC United States

Study Director

Cleveland Clinic
Cleveland, OH United States

Study Director

Northwest Dermatology
Portland, OR United States

Study Director

Suzanne Bruce & Associates, PA
Houston, TX United States